Skip to main content

Table 3 Correlation between PLOD2 expression and clinicopathological characteristics of laryngeal cancer patients

From: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

Characteristics PLOD2 χ2 test p Fisher’s exact test p
Low, no. cases (%) High, no. cases (%)
Clinical stage
 I&II 38 (64.4) 16 (29.1) < 0.001 < 0.001
 III&IV 21 (35.6) 39 (70.9)   
T classification
 T1& T2 42 (71.2) 17 (30.9) < 0.001 < 0.001
 T3& T4 17 (28.8) 38 (69.1)   
N classification
 N0 49 (83.1) 37 (67.3) 0.051 0.080
 N1& N2& N3 10 (16.9) 18 (32.7)   
M classification
 No 56 (94.9) 47 (85.5) 0.087 0.116
 Yes 3 (5.1) 8 (14.5)   
Expression of CD44
 Low expression 50 (84.7) 7 (12.7) < 0.001 < 0.001
 High expression 9 (15.3) 48 (87.3)   
Expression of CD133
 Low expression 46 (78.0) 16 (29.1) < 0.001 < 0.001
 High expression 13 (22.0) 39 (70.9)   
Age (years)
  < 62 30 (50.8) 26 (47.3) 0.703 0.712
  ≥ 62 29 (49.2) 29 (52.7)